drugset / Trial / NCT04006145
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
RandomizedParallel-groupTriple-blindTreatment
Summary
Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)
Timeline
- Start
- 2019-06-06
- Primary completion
- 2020-06-26
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elobixibat | Small molecule | 5 mg | — |